GSK Consumer Healthcare Korea was revealed to have appointed a new chief executive officer, and it was revealed to be Shin Dong Woo, a former CEO of the company’s branch in Hong Kong.
According to The Korea Times, GSK Consumer Healthcare Korea announced the assignment of CEO Shin earlier this week. It was reported that the new chief has been with the company for 28 years and has led GSK in various international businesses - from consumer health care to general consumer goods.
He also led other health care firms such as Pfizer and Sanofi. Prior to his assignment as the new chief at GSK Consumer Healthcare Korea, he has been leading the Honk Kong unit for the last two years. During his tenure, he has many achievements, including boosting the business and building the foundation for its stability.
At Sanofi Korea, he became the first president of the He also completed the company's integration with Pfizer Consumer Healthcare, where he was CEO of the Korean branch and the Asia-Pacific region between 2015 and 2020.
Shin also became the very first president of the French multinational healthcare company’s Korean unit. He helped established the brand in the country and introduced major products that are now selling very well here., and this is not all. Shin has extensive experience in marketing as well as he worked at Coca-Cola, L’Oreal, and Fox Home Entertainment and was in charge of marketing and sales for more than a decade.
Meanwhile, Shin will lead GSK Consumer Healthcare Korea, which has recently changed its name to Haleon. This will be the company’s official name as it starts its consumer healthcare venture. The name means the company will also change all of its product packaging.
"With the announcement of 'Haleon' today, we are one step closer to our goal of becoming a consumer healthcare company,” Haleon’s CEO-nominee, Brian McNamara, said in a press release in February. “'Haleon' will stand as a leader in the consumer healthcare industry with the vision of delivering better daily health to mankind.”
“Haleon” is the outcome of the successful merging of Novartis in 2015 and Pfizer's consumer healthcare portfolio in 2019 over the past eight years.


Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
Instagram Outage Disrupts Thousands of U.S. Users
Gold and Silver Prices Rebound After Volatile Week Triggered by Fed Nomination
India–U.S. Interim Trade Pact Cuts Auto Tariffs but Leaves Tesla Out
SoftBank Shares Slide After Arm Earnings Miss Fuels Tech Stock Sell-Off
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Dow Hits 50,000 as U.S. Stocks Stage Strong Rebound Amid AI Volatility
Japanese Pharmaceutical Stocks Slide as TrumpRx.gov Launch Sparks Market Concerns
Washington Post Publisher Will Lewis Steps Down After Layoffs
South Africa Eyes ECB Repo Lines as Inflation Eases and Rate Cuts Loom
U.S. Stock Futures Slide as Tech Rout Deepens on Amazon Capex Shock
Dollar Steadies Ahead of ECB and BoE Decisions as Markets Turn Risk-Off
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
FDA Targets Hims & Hers Over $49 Weight-Loss Pill, Raising Legal and Safety Concerns
Rio Tinto Shares Hit Record High After Ending Glencore Merger Talks 



